Introduction
============

There is convincing evidence from previous studies that patients with ulcerative colitis (UC) have a higher incidence of colorectal cancer (CRC), compared with the general population ([@b1-mmr-12-04-4947]). The increased incidence occurs predominantly in patients with long-standing extensive colitis ([@b2-mmr-12-04-4947]). Although CRC induced by UC only accounts for 1% of all cases of CRC in the general population, it is a serious sequel of the disease and accounts for one sixth of the mortality rate in patients with UC in Asia ([@b3-mmr-12-04-4947]).

Multiple existing genome association approaches have been suggested to account for the mechanism of CRC ([@b4-mmr-12-04-4947],[@b5-mmr-12-04-4947]), particularly its induction by UC, by identifying the independent effects of individual genes ([@b6-mmr-12-04-4947]). Suzuki *et al* identified a group of genes, which were preferentially hypermethylated in CRC, including *SFRP1* ([@b7-mmr-12-04-4947]). In a genome-scale analysis, 16% of colorectal carcinomas were found to be hypermutated and, excluding the hypermutated types of cancer, colon and rectal types of cancer had considerably similar patterns of genomic alteration ([@b8-mmr-12-04-4947]). However, investigations focussing on the effects of individual gene has omitted genes, which are not only encoded as individual genes or proteins, but also as subnetworks of interacting proteins within a larger human protein-protein interaction (PPI) network in the human genome ([@b9-mmr-12-04-4947]). As a result, several mechanisms of human disease, including CRC remain to be elucidated.

The availability of large protein networks provides one method to, at least partially, address the challenges mentioned above. Since large protein networks are available for humans ([@b10-mmr-12-04-4947]), a number of approaches have been demonstrated for extracting relevant functional pathways, based on the relevant databases ([@b11-mmr-12-04-4947]). Following the measurement of sufficient protein interaction data, a large number of distinct functional pathways can be identified, which enable novel opportunities for elucidating the pathways involved in major diseases and pathologies ([@b10-mmr-12-04-4947],[@b12-mmr-12-04-4947]). Investigations account for properties in interaction networks, and it has been reported that clustering with overlapping neighborhood expansion can be used as a method for detecting potentially overlapping protein complexes from a PPI network ([@b13-mmr-12-04-4947]).

Network enrichment and topological analysis identifies the target gene set within its interaction environment and identifies possible gene cofactors and topologically associated pathways and processes ([@b14-mmr-12-04-4947]). Several groups have suggested a more effective method of combining gene expression measurements in groups of genes that fall within certain pathways. Several approaches have been suggested to score known pathways or sub-networks on the coherency of expression changes among their member genes. For example, Chuang *et al* identified the markers of metastasis within gene expression profiles ([@b15-mmr-12-04-4947]), which involved the identification of gene alterations and prediction of the likelihood of metastasis in unknown samples using a protein-network-based approach. Pržulj *et al* performed a systematic graph theory-based analysis of this PPI network to construct computational models for describing and predicting the properties of life-threatening mutations and proteins involved in genetic interactions, functional groups, protein complexes and signaling pathways ([@b16-mmr-12-04-4947]). However, few investigations combining gene expression and network properties for measurements of groups of genes that fall within pathways and sub-networks have been performed.

The aim of the present study was to determine the formation mechanism of CRC induced by UC, using a combination of methods for the measurement of gene expression (genome-wide global significance; GWGS) and centralities. The analysis pipeline included analysis of differentially expressed (DE) genes, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, construction of PPI networks, module detection, measurements of topological factors, determination of GWGS values, and predictions of drug genes and miRNA target genes.

Materials and methods
=====================

Identification of gene expression datasets
------------------------------------------

A total of six data-sets, in cluding E-GEOD-6731 ([@b17-mmr-12-04-4947]), E-GEOD-36807, E-GEOD-38713 ([@b18-mmr-12-04-4947]), E-GEOD-41258 ([@b19-mmr-12-04-4947]), E-GEOD-4183 ([@b20-mmr-12-04-4947]), and E-MTAB-57 ([@b21-mmr-12-04-4947]), were extracted from the Array/Express database (<http://www.ebi.ac.uk/arrayexpress/>). For UC, the E-GEOD-6731 dataset consisted of four normal controls and nine patients; the E-GEOD-36807 dataset consisted of seven normal controls and 15 patients; the E-GEOD-38713 dataset consisted of 13 normal controls and 30 patients; the E-GEOD-41258 CRC dataset consisted of 100 normal controls and 290 patients; the E-GEOD-4183 data consisted of 18 normal controls and 35 patients; and the E-MTAB-57 dataset consisted of 22 normal controls and 25 patients.

Integrated analysis of DE genes
-------------------------------

The fold-change (FC) based on the model was used in the present study, as our computational evaluation aimed to identify the changes of gene expression. For each gene in the list of unique genes, a rank number was assigned, in descending order between 1 and *m*, according to their corresponding degree of differential expression. The present study then measured the GWRS of *i*-th gene in the *j*-th dataset, using the following equation ([@b1-mmr-12-04-4947],[@b22-mmr-12-04-4947]):

The number of datasets was denoted by *n*, the number of unique genes across *n* datasets was denoted by *m*; where r~ij~, *i*=1-*m*, *j*=1-*n*, indicate the rank number of the *i*-th gene in the *j*-th study. The range of GWRS values (*s~ij~*) was between 0 and -2log (1/m).

The GWGS of a gene was estimated based on its corresponding GWRS across the *n* datasets using the following equation ([@b2-mmr-12-04-4947]):

*ω~j~* represents the relative weight of the *j*-th dataset. The value of the weight was assigned based on the data quality of the *j*-th datasets, the value of *ω~j~* is used to reflect the differential importance of biopsy, vs. cell line samples which may be taken into account. The present study assigned equal weights to all data. In addition, the P-values for all genes were recorded following analysis using the Linear Models for Microarray Data (Limma) 3.20.8 package, subsequent to robust multiarray average (RMA) ([@b23-mmr-12-04-4947]) and preprocessing ([@b24-mmr-12-04-4947]). The genes with \|log2FC\|\>2 and P\<0.01 were selected as DE genes for further investigation. The DE genes were selected if the gene was identified as a DE gene in at least two datasets in each group (UC or CRC).

Pathway enrichment analysis
---------------------------

The Kyoto Encyclopedia of Genes and Genomes (KEGG) database is a knowledge base for the systematic analysis of gene functions, linking genomic information with higher order functional information. In the present study, KEGG pathway enrichment analysis was performed for the identified DE genes using the online tool Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Resources 6.7 (<http://david.abcc.ncifcrf.gov/>) ([@b25-mmr-12-04-4947]). KEGG pathways with P\<0.01 were selected, based on the expression analysis systematic explored (EASE) assessment, implemented in DAVID. The principle of EASE was as follows ([@b3-mmr-12-04-4947]): *n* is the number of background genes; *a′* is the gene number of one gene set in the gene lists; *a′* + *b* is the number of genes in the gene list, which include at least one gene set; *a′* + *c* is the gene number of one gene list in the background genes; *a* is replaced with *a′* = *a*−1.

Predictions of drug genes and miRNA targets
-------------------------------------------

The present study performed drug gene and miRNA target prediction using a Web-based gene set analysis toolkit (WebGestalt; <http://bioinfo.vanderbilt.edu/webgestalt/analysis.php>) ([@b26-mmr-12-04-4947]). If there are *n* genes in the CRC gene set of interest (A), *m* genes in the UC reference gene set (B), and there are *k* genes in CRC and *j* genes in UC in a given category (C). Based on the reference gene set, the expected value of k is *ke* = *(n / m) \* j*. If *k* exceeds the above expected value, category C is considered to be enriched, with a ratio of enrichment (*r*) determined by *r* = *k / ke*. If B represents the population from which the genes in A are obtained, WebGestalt uses the hypergeometric assessment to evaluate the significance of enrichment for category C in gene set A ([@b27-mmr-12-04-4947]), as in following equation ([@b4-mmr-12-04-4947]):

The P-values require adjustment for multiple assessments, which was performed using the Benjamini-Hochberg method ([@b28-mmr-12-04-4947]). Genes with quantities \>5 and P\<0.01 were considered significant.

Analysis and construction of the PPI network
--------------------------------------------

For protein interaction data, the present study utilized a human PPI dataset from the Search Tool for the Retrieval of Interacting Genes/proteins (STRING) 9.1 (<http://string.embl.de/>) resource. In addition, the PPI network was constructed using Cytoscape 3.1.0 ([@b29-mmr-12-04-4947]), a free software package for visualizing, modeling and analyzing the integration of bimolecular interaction networks with high-throughput expression data and other molecular states.

Molecular complex detection (MCODE) algorithm
---------------------------------------------

The MCODE algorithm (<http://baderlab.org/Software/MCODE>) was used for subnet analysis of the PPI network. The MCODE algorithm predominantly includes three stages: Vertex weighting, complex prediction and optionally post-processing. At the vertex weighting stage, all vertices, based on their local network density, were weighted using the highest *k*-core of the vertex neighborhood. At the stage of complex prediction, the vertex-weighted graph was taken as input, a complex with the highest-weighted vertex was seeded, and moved outward from the seed vertex recursively. It owned vertices in the complex whose weight was above a specific threshold, a certain percentage away from the weight of the seed vertex. Complexes with a core\<2 (graph of minimum degree 2) were filtered, the \'fluff\' option and \'haircut\' option were also run. The \'fluff\' option was used to increase the size of the complex, according to a given \'fluff\' parameter between 0.0 and 1.0. The \'haircut\' option removed vertices, which were connected to the core complex alone, resulting in complexes obtained that were 2-core When both options were performed, \'fluff\' runs followed by haircut, the available network properties were as follows: The degree of a node (gene or protein) was the average number of edges (interactions) incident to this node. The degree quantified the local topology of each gene, by combing the number of its adjacent genes ([@b30-mmr-12-04-4947]). This produced a simple count of the number of interactions of a given node.

The node betweenness, *B(v)*, of a node, *v*, was calculated from the number of shortest paths (σ*~st~*) between nodes *s* and *t* going through *v* ([@b5-mmr-12-04-4947]):

GWGS values were based on log2FC, which represented their corresponding degree of differential expression, with genes of a higher degree of differential expression ranked higher.

Results
=======

Identification of DE genes
--------------------------

The value of GWGS was used for integrated analyses of the independent microarray investigations. A gene witha high GWGS value was considered to be globally significant across multiple independent investigations. GWGS can be obtained based on the fold-change, *t*-test and significance analysis microarrays (SAM) ([@b31-mmr-12-04-4947]). In the present study, the fold-change-based algorithm was more suitable for measurement of the significance of differential expression, since the present study aimed to examine the association between gene expression and network properties. By using the intersection of the microarray datasets, 217 DE genes for were obtained for CRC and 341 DE genes were obtained for UC. In addition, DE genes present in CRC and UC were identified as common genes, and 62 common genes were identified ([Table I](#tI-mmr-12-04-4947){ref-type="table"}).

KEGG analysis
-------------

The KEGG pathway database is a collection of manually drawn pathway maps for metabolism, genetic information processing, environmental information processing, including signal transduction, and various other cellular processes and human diseases ([@b32-mmr-12-04-4947]). Pathway enrichment analysis of CRC revealed nine enriched terms ([Table II](#tII-mmr-12-04-4947){ref-type="table"}), the most significant term was focal adhesion (P=6.82E-004), which contained several genes, including *CAV1*, *CCND1* and *PAK2*. In UC, five enriched terms ([Table III](#tIII-mmr-12-04-4947){ref-type="table"}) were obtained, the most important of which was ECM-receptor interaction (P=1.09E-005), which consisted of genes, including *LAMA1*, *VWF* and *COL4A2*. Focal adhesion and the chemokine signaling pathway were presented in CRC and UC.

Drug gene interaction predictions
---------------------------------

In the prediction of drug-gene interactions of CRC, the genes were found to be associated with 25 drugs, including collagenase (P=3.88E-21), estradiol (P=6.81E-10) and progesterone (P=1.98E-09; [Table IV](#tIV-mmr-12-04-4947){ref-type="table"}). A total of 21 drugs were found to be associated with genes in UC, including collagenase (P=1.02E-20), heparin (P=1.45E-14) and urokinase (P=1.46E-08; [Table V](#tV-mmr-12-04-4947){ref-type="table"}). The collagenase, progesterone, heparin, urokinase, nadh and adenosine drugs were identified in both UC and CRC.

miRNA target gene prediction
----------------------------

In the prediction of miRNAs in CRC, 27 terms were identified ([Table VI](#tVI-mmr-12-04-4947){ref-type="table"}), and the most significant three terms were TACTTGA (MIR-26A and MIR-26B), AATGTGA (MIR-23Aand MIR-23B) and CAGTATT (MIR-200B, MIR-200C and MIR-429). In UC, miRNA prediction revealed 43 terms of miRNA target genes ([Table VII](#tVII-mmr-12-04-4947){ref-type="table"}), the most significant three terms were TACTTGA (MIR-26A and MIR-26B), TGGTGCT (MIR-29A, MIR-29B and MIR-29C) and TGCCTTA (MIR-124A).

PPI network construction and analysis
-------------------------------------

In the present study, PPI networks were constructed for the DE genes in CRC and UC. In the network, nodes represent DE genes and edges between the nodes represent interaction of genes in the network. In the CRC network, there were 210 nodes and 752 edges, which included 217 DE genes ([Fig. 1](#f1-mmr-12-04-4947){ref-type="fig"}). Among the nodes, *MT2A* was identified with the highest degree at 42, followed by *COL1A1* at 37 and *COL1A2* at 37. In the UC network, there were 314 nodes, 882 edges and 341 DE genes ([Fig. 2](#f2-mmr-12-04-4947){ref-type="fig"}). *CD44* was identified with the highest degree, at 52, followed by *IL1B* at 50 and *MMP9* at 49.

Clusters
--------

When the Node Score Cut-off=0.2, the Degree Cut-off=4, the *k*-core=4 and the maximum depth was set at 100, for CRC, three clusters were obtained ([Fig. 3](#f3-mmr-12-04-4947){ref-type="fig"}). Cluster 1 had the highest score (5.8) and number of edges (29 edges), the nodes of the three clusters were identical. A total of six common genes were present in UC and CRC in Cluster 1: *COL1A2*, *MMP3, PLAU, CXCL5, CXCL3* and *CXCL1.* In Cluster 2, *MMP7, BGN, MMP1, SPP1* and *COL1A1* were common to UC and CRC. There were four common genes in Cluster 3: *SORD*, *MT1 M*, *MMP9* and *LCN2.*

For UC, three clusters were obtained ([Fig. 4](#f4-mmr-12-04-4947){ref-type="fig"}). Cluster 1 had the highest score (5.867), numbers of nodes (16 nodes) and number of edges (44 edges). There were five common genes present in UC and CRC in Cluster 1 (*COLIAI, SPP1, COL1A2, BGN* and *MMP9*), four in Cluster 2 (*CXCL5, MMP1, MMP7* and *PLAU*) and four in Cluster 3 (*LCN2*, *OLFMA*, *PTN* and *REG1B*).

Analysis of network properties
------------------------------

The degree and betweenness centralities for the clusters in CRC and UC were calculated. As shown in [Fig. 5](#f5-mmr-12-04-4947){ref-type="fig"}, the topological centrality-based degree among the clusters revealed that Cluster 2 of UC had the highest degree at 29), while Cluster 3 of UC had the lowest degree at 13. As shown in [Fig. 6](#f6-mmr-12-04-4947){ref-type="fig"}, the betweenness of Cluster 3 also had the lowest betweenness (0.02). GWGS is closely associated with log2FC and indicates the corresponding degree of the DE genes, with DE genes of a higher degree exhibiting higher ranking values. As shown in [Fig. 7](#f7-mmr-12-04-4947){ref-type="fig"}, no significant difference was observed in the rank values between CRC and UC. On comparison of the clusters in CRC, Cluster 1 had the highest rank value (5.02), while cluster 3 of UC had the highest rank value (5.91).

Discussion
==========

In the present study, DE genes with GWGS values in CRC and UC were identified through integrated analysis of multiple high throughput data. Based on the DE genes, PPI networks were constructed using the STRING database, and MCODE algorithm was implemented for sub-network detection. The significance of sub-networks was identified based on the network properties and GWGS values. In addition, functional enrichment analysis, including KEGG enrichment analysis, drug-gene interaction prediction, and miRNA prediction, were performed.

A total of 217 DE genes of CRC, 341 DE genes of UC and 62 common genes were identified. The KEGG pathway analysis revealed nine terms of CRC and five terms of UC, with the focal adhesion and chemokine signaling pathway presented in both. As for the prediction of drug-gene interactions, collagenase was important in the drug associated genes of CRC and UC. The most significant miRNA prediction term in CRC and UC was the same, TACTTGA (MIR-26A and MIR-26B). The entire PPI network was constructed and subnetwork analyzed, the clusters contained common genes and exhibited similarities between CRC and UC. No significant difference was observed between the GWGS values of the clusters in UC and CRC. In UC, cluster 3 had the highest GWGS value, while the topological centrality of this cluster had the lowest degree and betweenness.

Patients with UC have an increased risk of developing CRC, compared with the general population ([@b33-mmr-12-04-4947]), and the increased risk was almost entirely confined to patients with long-standing extensive colitis ([@b3-mmr-12-04-4947]). Important risk factors include primary sclerosing cholangitis ([@b34-mmr-12-04-4947]) and a family history of CRC ([@b35-mmr-12-04-4947]), whereas the role of other factors, including the effect of the age at onset of UC remains to be elucidated. It has been reported that hypermethylation of the promoter region of *CDH1* in CRC is associated with a reduction in UC ([@b36-mmr-12-04-4947]). In the present study, 62 common genes were found between CRC and UC. The most significant two genes were *AQP8* and *CXCL5*. *AQP8* is a water channel protein, and aquaporins are a family of small integral membrane proteins associated with major intrinsic protein, and is closely associated with miRNA in patients with UC patients ([@b37-mmr-12-04-4947]). Thus, it is possible that certain genes expressed in patients with UC are also expressed in patients with CRC, and the inhibition of certain genes in UC may decrease risk of CRC.

The focal adhesion and chemokine signaling pathway were found to be present in CRC and UC. It has been previously revealed that the predominant type of pathway in UC-associated neoplasia is associated with genes and, that genomic instability frequently occurs prior to the development of histologically-defined dysplasia ([@b38-mmr-12-04-4947]). Using genes to construct a predictive model to distinguish patients with and without UC-induced CRC is a useful method to identify the disease ([@b38-mmr-12-04-4947]). Therefore, controlling the pathway of UC to prevent the formation of UC-associated neoplasia may decrease the incidence of CRC.

The present study demonstrated that collagenase, progesterone, heparin, urokinase, nadh and adenosine drugs may be used to treat CRC and UC. Due to this possible mechanism for inflammation-induced cancer, patients taking anti-inflammatory mesalamine drugs may exhibit reduced rates of colorectal neoplasia ([@b39-mmr-12-04-4947]). These results were concordant with the hypothesis that certain drugs may offer potential for use in the treatment of CRC and UC. For example, collagenases, are proteolytic enzymes, which are present within cells in an inactive form and are secreted at sites of inflammation by mononuclear cells and metastatic tumors ([@b40-mmr-12-04-4947]), thus, collagenase not only indicates the potential for preventing UC from inflammation interference, but also a potential effect on tumors, which lead to cancer.

Previous studies have demonstrated that miRNAs are the central regulators of various physiological processes, and that the disruption of miRNA is associated with human diseases ([@b41-mmr-12-04-4947],[@b42-mmr-12-04-4947]). Therefore, in the present study, miRNA prediction experiments were performed. The most significant miRNA in CRC was the same as that in UC. Therefore, the disruption of miRNA in UC may lead alter miRNA in CRC. The link between miRNA function and cancer pathogenesis was further supported by investigations examining miRNA in clinical samples, with altered miRNA being reported in CRC ([@b43-mmr-12-04-4947]). The present study hypothesized that the altered miRNA in CRC was from UC.

The examination of networks as a tool has attracted significant attention in analyzing several biological and communication systems. Protein interaction network analysis provides an effective method of estimating and understanding the likelihood of potential, yet undetermined, connections between proteins/genes ([@b44-mmr-12-04-4947]). In PPI networks, the data of large-scale protein interactions has accumu-lated with the development of high throughput assessment technology, however, a certain number of interactions have not been assessed, which may be important. This type of difficulty had been resolved to a certain extent by the use of clustering methods, which had previously been found to be useful in identifying protein/gene interactions within the same cellular process ([@b45-mmr-12-04-4947]). In the present study, the MCODE algorithm was applied to examine gene-gene connectivity in a more informative way, which revealed three clusters in CRC and UC with highly connected nodes. Several common genes were contained in the clusters, which indicated that the clusters of CRC and UC had certain similarities. Srihari and Ragan performed a straightforward, systematic identification and comparison of modules across pancreatic normal and cancer tissue conditions by integrating PPI, gene-expression and mutation data ([@b46-mmr-12-04-4947]), which provided functional insight into the identified sub-network and thus may be suitable for analysis of CRC.

In several PPI networks, significance is correlated with the topological placement of the proteins/genes in the network, while connectivity provides an indication of the importance of a gene ([@b47-mmr-12-04-4947]). In the present study, the highest ranking gene in degree and betweenness centralities was *PLAU* in both UC and CRC. This gene encodes a serine protease, which is involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation ([@b48-mmr-12-04-4947]). A specific polymorphism in this gene may be associated with late-onset ([@b49-mmr-12-04-4947]). However, the GWGS value of Cluster 2 in UC was not in accordance with the degree of betweenness. GWGS was a novel method to detect the relevance of genes between clusters, based on the rank value of gene expression. In previous studies, the topological centrality, based on degree, was not consistent with that based on betweenness, even altered rules of the same clusters in degree, betweenness, closeness and other properties (such as cluster coefficient and stress) were different ([@b50-mmr-12-04-4947],[@b51-mmr-12-04-4947]). Differences among these properties may be explained by the fact that each property has its own target ([@b52-mmr-12-04-4947]); for example GWGS focuses on combining gene expression with the protein network, while the degree concerns the association between genes. Investigation of the worth of rank values in gene signatures and biological analysis is required in the future.

In conclusion, the present study demonstrated the presence of 62 common genes in CRC and UC DE genes and KEGG analysis obtained the same gene terms, therefore, controlling these terms in UC may decrease the risk and rate of CRC formation. Through drug genes prediction, drugs were identified, which may treat UC and CRC simultaneously to cure patients with UC and possibly prevented patients from developing CRC. According to PPI network analysis, a significant PPI network and subnet was produced, with common genes included in clusters. No significant differences were observed in the GWGS values of the clusters in UC and CRC. Cluster 3 in UC had the highest GWGS value, whereas the topological centrality of Cluster 3 in UC had the lowest degree and betweenness. These findings may provide potential biomarkers and reveal information regarding the pathological mechanism of CRC induced by UC.

This study was supported by the Shandong Province scientific and technological project (grant. no. 2012G0021830).

![Protein-protein interaction network of colorectal cancer DE genes. A total of 210 node (purple ovals) and 752 edges (lines between) were identified, which included 217 DE genes. Among the nodes, *MT2A* exhibited the highest degree ([@b42-mmr-12-04-4947]), followed by *COL1A1* ([@b37-mmr-12-04-4947]) and *COL1A2* ([@b37-mmr-12-04-4947]). Node sizes correspond to the absolute values of the fold change of the DE gene. Edges were derived from the Search Tool for the Retrieval of Interacting Genes/proteins database. DE, differentially expressed.](MMR-12-04-4947-g05){#f1-mmr-12-04-4947}

![Protein-protein interaction network of ulcerative colitis DE genes. A total of 314 nodes (purple ovals), 882 edges (lines between nodes) and 341 DE genes were identified, where nodes represent gene signatures and edges between nodes represent interaction between genes in the network. Among the nodes, *CD44* exhibited the highest degree ([@b52-mmr-12-04-4947]), followed by *IL1B* ([@b50-mmr-12-04-4947]) and *MMP9* ([@b49-mmr-12-04-4947]). Node sizes correspond to the absolute values of the fold change of the DE genes. Edges were derived from he Search Tool for the Retrieval of Interacting Genes/proteins database. DE, differentially expressed.](MMR-12-04-4947-g06){#f2-mmr-12-04-4947}

![Clusters of the protein-protein interaction network of CRC. (A) Cluster 1, (B) Cluster 2 and (C) Cluster 3. Clusters were identified according to the following cut off-values: Node Score=0.2, degree=4, *k*-core=4, Maximum depth=100. Cluster 1 had the highest degree (5.8) and number of edges ([@b29-mmr-12-04-4947]), the nodes of the three clusters were same. Common genes to CRC and ulcerative colitis in Cluster 1 were *COL1A2, MMP3, PLAU, CXCL5, CXCL3* and *CXCL1*. In Cluster 2, common genes were *MMP7, BGN, MMP1, SPP1*, and *COL1A1*. There were four common genes in Cluster 3 (*SORD, MT1 M, MMP9* and *LCN2*). Node sizes correspond to the absolute values of the fold change of the differentially expressed genes. Edges were derived from the Search Tool for the Retrieval of Interacting Genes/proteins database; CRC, colorectal cancer.](MMR-12-04-4947-g07){#f3-mmr-12-04-4947}

![Clusters of the protein-protein interaction network in UC. (A) Cluster 1, (B) cluster 2 and (C) cluster 3. Cluster 1 had the highest degree (5.867), and numbers of nodes ([@b16-mmr-12-04-4947]) and edges ([@b44-mmr-12-04-4947]). There were five common genes to UC and colorectal cancer in cluster 1 (*COLIAI, SPP1, COL1A2, BGN* and *MMP9*), four in cluster 2 (*CXCL5, MMP1, MMP7* and *PLAU*) and four in cluster 3 (*LCN2, OLFMA, PTN* and *REG1B*). Node sizes correspond to the absolute values of the fold change of the differentially expressed genes. Edges were derived from the Search Tool for the Retrieval of Interacting Genes/proteins database. UC, ulcerative colitis.](MMR-12-04-4947-g08){#f4-mmr-12-04-4947}

![Centralities analysis based on the degree of the clusters. (A) Cluster 1 of CRC; (B) cluster 2 of CRC; (C) cluster 3 of CRC; (D) cluster 1 of UC; (E) cluster 2 of UC; (F) cluster 3 of UC. No significant differences were observed between the degrees of the clusters in CRC. Cluster 2 of UC had the highest degree ([@b29-mmr-12-04-4947]), while Cluster 3 of UC had the lowest degree ([@b13-mmr-12-04-4947]). CRC, colorectal cancer; UC, ulcerative colitis.](MMR-12-04-4947-g09){#f5-mmr-12-04-4947}

![Centralities analysis based on the betweenness of clusters. (A) Cluster 1 of CRC; (B) cluster 2 of CRC; (C) cluster 3 of CRC; (D) cluster 1 of UC; (E) cluster 2 of UC; (F) cluster 3 of UC. Cluster 2 of UC had the highest betweenness, while cluster 3 of UC possessed the lowest betweenness. CRC, colorectal cancer; UC, ulcerative colitis.](MMR-12-04-4947-g10){#f6-mmr-12-04-4947}

![Rank values of the clusters. (A) Cluster 1 of CRC; (B) cluster 2 of CRC; (C) cluster 3 of CRC; (D) cluster 1 of UC; (E) cluster 2 of UC; (F) cluster 3 of UC. No significant differences were observed between the rank values of the clusters in CRC and UC. CRC, colorectal cancer; UC, ulcerative colitis.](MMR-12-04-4947-g11){#f7-mmr-12-04-4947}

###### 

Genes common to colorectal cancer and ulcerative colitis.

  Number   Gene
  -------- -----------
  1        AQP8
  2        CXCL5
  3        MMP3
  4        CHI3L1
  5        KIAA1199
  6        TMEM158
  7        CXCL3
  8        MMP1
  9        CXCL1
  10       ABCA8
  11       SPP1
  12       PSAT1
  13       SLC26A2
  14       SLC7A11
  15       SLC4A4
  16       PHLDA1
  17       OLFM4
  18       MMP7
  19       GUCA2B
  20       CWH43
  21       LCN2
  22       REG1A
  23       BGN
  24       NFE2L3
  25       SULF1
  26       PRKACB
  27       CHP2
  28       PTN
  29       TRIM29
  30       COL1A1
  31       CDH3
  32       NR5A2
  33       HPGD
  34       SLCO4A1
  35       NXPE4
  36       COL1A2
  37       PLAU
  38       HMGCS2
  39       CFB
  40       SERPINB5
  41       SPINK4
  42       CD55
  43       MT1M
  44       MMP12
  45       SGK2
  46       SLC17A4
  47       PCK1
  48       SORD
  49       PADI2
  50       TNFRSF12A
  51       REG1B
  52       ANK3
  53       REG3A
  54       EPHX2
  55       ABCB1
  56       OSBPL1A
  57       LOXL2
  58       WNT5A
  59       ENTPD5
  60       COL5A2
  61       MMP9

###### 

Kyoto Encyclopedia of Genes and Genome analysis of differentially expressed genes in colorectal cancer.

  Term                                              Genes                                                                             P-value
  ------------------------------------------------- --------------------------------------------------------------------------------- ----------
  hsa04510:Focal adhesion                           CAV1, CCND1, PAK2, VEGFA, COL1A2, COL1A1, FLNC, COL5A2, THBS2, MYLK, SPP1, MYL9   6.82E-04
  hsa05219:Bladder cancer                           CCND1, IL8, MMP9, VEGFA, MYC, MMP1                                                7.49E-04
  hsa03320:PPAR signaling pathway                   SORBS1, HMGCS2, SCD, FABP4, FABP1, MMP1, PCK1                                     1.20E-03
  hsa04270:Vascular smooth muscle contraction       KCNMA1, EDNRA, ACTG2, PPP1R12B, MYH11, PRKACB, MYLK, MYL9                         3.25E-03
  hsa00910:Nitrogen metabolism                      CA12, CA4, CA2, CA1                                                               7.13E-03
  hsa00150:Androgen and estrogen metabolism         UGT2B17, HSD17B2, HSD11B2, UGT2B15                                                2.62E-02
  hsa04060:Cytokine-cytokine receptor interaction   CXCL1, INHBA, IL8, CXCL5, CCL20, TNFRSF12A, CXCL3, CXCL2, VEGFA, CXCL12           3.85E-02
  hsa04062:Chemokine signaling pathway              CXCL1, IL8, CXCL5, CCL20, CXCL3, CXCL2, PRKACB, CXCL12                            4.44E-02
  hsa00140:Steroid hormone biosynthesis             UGT2B17, HSD17B2, HSD11B2, UGT2B15                                                4.58E-02

###### 

Kyoto Encyclopedia of Genes and Genome analysis of differentially expressed genes in ulcerative colitis.

  Term                                            Genes                                                                                              P-value
  ----------------------------------------------- -------------------------------------------------------------------------------------------------- ----------
  hsa04512:ECM-receptor interaction               LAMA1, VWF, COL4A2, COL4A1, CD44, TNC, COL3A1, COL1A2, COL1A1, COL5A2, COL5A1, SPP1                1.09E-05
  hsa04610:Complement and coagulation cascades    VWF, CD55, THBD, CFB, C4BPB, C4BPA, CFI, PLAU, PLAUR                                               4.28E-04
  hsa04510:Focal adhesion                         COL4A2, VAV3, COL4A1, TNC, COL3A1, COL5A2, COL5A1, VWF, LAMA1, COL1A2, ZYX, COL1A1, PIK3R3, SPP1   2.42E-03
  hsa04062:Chemokine signaling pathway            CCL11, CXCL1, VAV3, CXCL5, CXCL3, CXCL9, CXCL6, PRKACB, PIK3R3, CXCL11, STAT1, CXCL10              1.04E-02
  hsa04670:Leukocyte transendothelial migration   CLDN8, ICAM1, VAV3, NCF2, MMP9, PECAM1, CLDN1, PIK3R3                                              3.66E-02

###### 

Results of drug genes prediction in colorectal cancer.

  Drug                 C-value   P-value
  -------------------- --------- ----------
  Collagenase          104       3.88E-21
  Estradiol            122       6.81E-10
  Progesterone         136       1.98E-09
  Cisplatin            135       3.04E-08
  Fluorouracil         68        5.37E-08
  Acetazolamide        26        1.82E-07
  Heparin              188       5.15E-07
  Estrone              64        8.66E-07
  Gentamicin           71        1.61E-06
  Ciprofloxacin        111       1.57E-06
  Sodium bicarbonate   42        2.20E-06
  Urokinase            80        3.25E-06
  Indomethacin         45        3.12E-06
  Dexamethasone        89        6.05E-06
  Daunorubicin         93        7.81E-06
  Netilmicin           97        9.95E-06
  Cefacetrile          100       1.19E-05
  Cefotaxime           100       1.19E-05
  Doxorubicin          103       1.40E-05
  Tamoxifen            74        3.66E-05
  Etoposide            125       4.21E-05
  Hyaluronan           94        1.00E-04
  Nadh                 243       1.50E-03
  Adenosine            477       3.00E-03
  Glutathione          341       2.92E-02

###### 

Results of drug genes prediction in ulcerative colitis.

  Drug                      C-value   P-value
  ------------------------- --------- ----------
  Collagenase               104       1.02E-20
  Heparin                   188       1.45E-14
  Urokinase                 80        1.46E-08
  Alteplase                 86        2.79E-08
  Adenine                   159       6.18E-08
  Amiloride                 61        5.28E-07
  Nadh                      243       4.15E-06
  Immune globulin           624       1.13E-05
  Cyclosporine              56        8.01E-05
  Dinoprostone              61        8.97E-05
  Rosuvastatin              134       9.74E-05
  Adenosine monophosphate   102       2.48E-04
  Glycine                   191       7.99E-04
  Progesterone              136       8.01E-04
  Bupropion                 108       1.72E-03
  Adenosine triphosphate    299       2.70E-03
  Tretinoin                 126       3.34E-03
  Nitric oxide              131       3.91E-03
  Adenosine                 477       4.85E-03
  Vitamin a                 145       5.93E-03
  Phosphoric acid           159       8.71E-03

###### 

Results of miRNA prediction in colorectal cancer.

  miRNA                                                                                                                                       C-value   P-value
  ------------------------------------------------------------------------------------------------------------------------------------------- --------- ----------
  hsa_TACTTGA, MIR-26A, MIR-26B                                                                                                               297       3.64E-07
  hsa_AATGTGA, MIR-23A, MIR-23B                                                                                                               417       1.53E-06
  hsa_CAGTATT, MIR-200B, MIR-200C, MIR-429                                                                                                    465       4.67E-06
  hsa_TATTATA, MIR-374                                                                                                                        284       0.99E-05
  hsa_TGAATGT, MIR-181A, MIR-181B, MIR-181C, MIR-181D                                                                                         479       2.01E-04
  hsa_CTTGTAT, MIR-381                                                                                                                        201       6.11E-04
  hsa_TTTTGAG, MIR-373                                                                                                                        222       9.23E-04
  hsa_ATGAAGG, MIR-205                                                                                                                        156       1.21E-03
  hsa_TGGTGCT, MIR-29A, MIR-29B, MIR-29C                                                                                                      515       1.24E-03
  hsa_AAGCCAT, MIR-135A, MIR-135B                                                                                                             332       1.49E-03
  hsa_TGCCTTA, MIR-124A                                                                                                                       542       1.82E-03
  hsa_ACTGTGA, MIR-27A, MIR-27B                                                                                                               465       2.50E-03
  hsa_TGTTTAC, MIR-30A-5P, MIR-30C, MIR-30D, MIR-30B, MIR-30E-5P                                                                              572       5.52E-03
  hsa_ATTCTTT, MIR-186                                                                                                                        270       2.52E-03
  hsa_CTACCTC, LET-7A, LET-7B, LET-7C, LET-7D, LET-7E, LET-7F, MIR-98, LET-7G, LET-7I                                                         384       3.41E-03
  hsa_TTTGCAC, MIR-19A, MIR-19B                                                                                                               511       4.52E-03
  hsa_CACCAGC, MIR-138                                                                                                                        223       5.54E-03
  hsa_TAATAAT, MIR-126                                                                                                                        220       5.20E-03
  hsa_AAGCACT, MIR-520F                                                                                                                       236       6.90E-03
  hsa_TTTGTAG, MIR-520D                                                                                                                       335       7.11E-03
  hsa_GTTTGTT, MIR-495                                                                                                                        252       9.05E-03
  hsa_GTGCCTT, MIR-506                                                                                                                        714       1.02E-02
  hsa_TGCTGCT, MIR-15A, MIR-16, MIR-15B, MIR-195, MIR-424, MIR-497                                                                            593       1.05E-02
  hsa_ACCAAAG, MIR-9                                                                                                                          493       1.26E-02
  hsa_CTTTGTA, MIR-524                                                                                                                        431       2.21E-02
  hsa_TGCTTTG, MIR-330                                                                                                                        331       2.61E-02
  hsa_AGCACTT, MIR-93, MIR-302A, MIR-302B, MIR-302C, MIR-302D, MIR-372, MIR-373, MIR-520E, MIR-520A, MIR-526B, MIR-520B, MIR-520C, MIR-520D   336       2.76E-02

MIR/miRNA, microRNA.

###### 

Results of miRNA prediction in ulcerative colitis.

  miRNA                                                                                 C-value   P-value
  ------------------------------------------------------------------------------------- --------- ----------
  hsa_TACTTGA, MIR-26A, MIR-26B                                                         297       1.25E-07
  hsa_TGGTGCT, MIR-29A, MIR-29B, MIR-29C                                                515       8.93E-07
  hsa_TGCCTTA, MIR-124A                                                                 542       1.78E-06
  hsa_CAGTATT, MIR-200B, MIR-200C, MIR-429                                              465       5.17E-06
  hsa_CATTTCA, MIR-203                                                                  284       1.79E-05
  hsa_GTGCCAA, MIR-96                                                                   301       3.05E-05
  hsa_ACCAAAG, MIR-9                                                                    493       2.03E-04
  hsa_ACTGTGA, MIR-27A, MIR-27B                                                         465       4.06E-04
  hsa_AATGTGA, MIR-23A, MIR-23B                                                         417       5.11E-04
  hsa_TTTGCAC, MIR-19A, MIR-19B                                                         511       8.05E-04
  hsa_CTACCTC, LET-7A, LET-7B, LET-7C, LET-7D, LET-7E, LET-7F, MIR-98, LET-7G, LET-7I   384       1.00E-03
  hsa_TTGGAGA, MIR-515-5P, MIR-519E                                                     145       1.10E-03
  hsa_CACCAGC, MIR-138                                                                  223       2.00E-03
  hsa_AAGCCAT, MIR-135A, MIR-135B                                                       332       1.44E-03
  hsa_TGAATGT, MIR-181A, MIR-181B, MIR-181C, MIR-181D                                   479       1.61E-03
  hsa_TAATAAT, MIR-126                                                                  220       1.90E-03
  hsa_AAGCAAT, MIR-137                                                                  217       1.74E-03
  hsa_TATTATA, MIR-374                                                                  284       1.99E-03
  hsa_CTATGCA, MIR-153                                                                  214       1.63E-03
  hsa_AACTGGA, MIR-145                                                                  231       2.51E-03
  hsa_ATACCTC, MIR-202                                                                  178       3.01E-03
  hsa_CAGTGTT, MIR-141, MIR-200A                                                        308       3.20E-03
  hsa_GTGCAAT, MIR-25, MIR-32, MIR-92, MIR-363, MIR-367                                 308       3.22E-03
  hsa_AAGCACA, MIR-218                                                                  395       4.32E-03
  hsa_AAAGACA, MIR-511                                                                  199       5.11E-03
  hsa_TGTTTAC, MIR-30A-5P, MIR-30C, MIR-30D, MIR-30B, MIR-30E-5P                        572       6.02E-03
  hsa_TGTATGA, MIR-485-3P                                                               148       6.49E-03
  hsa_CAGCAGG, MIR-370                                                                  153       7.41E-03
  hsa_ATGAAGG, MIR-205                                                                  156       8.03E-03
  hsa_ACATTCC, MIR-1, MIR-206                                                           293       8.92E-03
  hsa_CTGAGCC, MIR-24                                                                   229       9.81E-03
  hsa_TAGCTTT, MIR-9                                                                    234       1.09E-02
  hsa_AAGCACT, MIR-520F                                                                 236       1.13E-02
  hsa_TTGCCAA, MIR-182                                                                  324       1.48E-02
  hsa_GCAAAAA, MIR-129                                                                  183       1.52E-02
  hsa_ATACTGT, MIR-144                                                                  198       2.06E-02
  hsa_ATTCTTT, MIR-186                                                                  270       2.05E-02
  hsa_CTTGTAT, MIR-381                                                                  201       2.16E-02
  hsa_CTTTGTA, MIR-524                                                                  431       2.18E-02
  hsa_TTTGCAG, MIR-518A-2                                                               208       2.48E-02
  hsa_ATATGCA, MIR-448                                                                  208       2.48E-02
  hsa_TGCACTG, MIR-148A, MIR-152, MIR-148B                                              299       3.16E-02
  hsa_ATGTACA, MIR-493                                                                  312       3.77E-02

MIR/miRNA, microRNA.
